Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRAFT Blue Z
- Development stage
- Unknown
- Lead developer
- DEMECAN
- Modality
- Small Molecules
- Administration
- Inhalation, Oral
01
Overview
CRAFT Blue Z (specifically CRAFT Blue Z 20:01) is an unirradiated medical cannabis flower product developed and produced in Germany by DEMECAN. It is derived from the Blue Zushi cultivar, which is an Indica-dominant hybrid cross of Zkittlez and Kush Mints. The product contains approximately 20.0% tetrahydrocannabinol (THC) and ≤1.0% cannabidiol (CBD). It is prescribed for the treatment of various conditions including chronic pain, stress, depression, headaches, and appetite loss, and is typically administered via inhalation or oral preparation.
- Brand names
- CRAFT Blue Z 20:01Demecan Craft Blue Z 20/1
- Other names
- Blue ZBlue Zushi
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on CRAFT Blue Z.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRAFT Blue Z.